Anemia treatment

Article written and reviewed by Dr Luca Moretti

Anemia is a reduction in hemoglobin defined in relation to age, sex and physiological status. Its clinical impact depends on severity, speed of onset, cause and cardiopulmonary reserve; not every form has profound effects on every organ. Treatment combines etiologic correction, support and prevention of complications when indicated. Understanding the many facets of anemia therapy means not only knowing the pharmacological and transfusion options, but also knowing how to adapt them to the specific characteristics of each patient, the severity of the clinical picture, the temporal course of the disease and the presence of other concomitant conditions.

Anemia may present acutely, requiring urgent and often temporary interventions, or may evolve slowly into a chronic form requiring targeted, continuous and long-term treatment. In both situations, personalization of the therapeutic approach is key to reducing risk and optimizing clinical outcomes.

Foundations of therapy: from diagnosis to strategic choice

For any therapeutic pathway to be effective, it must begin with an accurate diagnosis of the primary cause of anemia. Only in this way can the very real risk of treating only the symptom rather than the underlying disease be avoided. Anemia therapy is never a universal treatment, but must be adapted to etiology, speed of onset, severity of the hemoglobin deficit and the patient's overall condition.

In acute symptomatic anemia, such as massive blood loss, the priority is to control bleeding and restore perfusion and circulating volume with balanced resuscitation; transfusion of packed red blood cells restores oxygen-carrying capacity when indicated. In these settings, management must be timely and multidisciplinary, with particular attention to the risk of heart failure, myocardial ischemia and shock.

In chronic forms, the diagnostic and therapeutic pathway is more complex and is based on several fundamental steps:

• Classification of the type of anemia on the basis of morphologic and laboratory parameters, for example microcytic, macrocytic or normocytic, and deficiency, hemolytic or ineffective-production anemia;
• Identification of the specific etiologic cause: iron deficiency, vitamin deficiencies, renal or hepatic disease, bone marrow disorders, hemoglobinopathies and chronic inflammatory diseases;
• Assessment of severity and clinical impact by evaluating symptoms such as fatigue, dyspnea, tachycardia, angina and cognitive changes, objective signs and compensation of target organs;
• Selection of the most appropriate therapeutic strategy, adjusting the intensity, duration and combination of interventions according to the rate of progression, comorbidities and individual risks.

Integrating these elements makes it possible to establish truly effective treatment that does not merely correct the symptom but acts on pathogenic mechanisms and prevents recurrence.

Goals of therapy: personalization and clinical rationale

The main goals of anemia treatment are:

• Correct or remove the underlying cause, through etiologic treatment;
• Restore hemoglobin levels and oxygen delivery compatible with patient wellbeing and safety;
• Prevent and manage complications both of anemia itself, such as heart failure, myocardial ischemia, neurocognitive changes and falls in older adults, and of treatment, such as transfusion reactions or drug toxicity;
• Improve quality of life and functional independence, especially in patients with chronic or refractory anemia or receiving multiple therapies.

When developing the treatment plan, factors such as age, other diseases, the speed at which anemia develops and the clinical context, for example pregnancy, cancer, organ failure or chronic infections, must be considered. Treatment may therefore range from simple correction of a nutritional deficiency, to the use of erythropoietin and its analogs, to the need for blood transfusions or advanced therapies for the most severe and rare forms.

Choice and adjustment of therapy: from deficiency forms to chronic and genetic anemias

Anemia treatment varies substantially according to the underlying pathophysiological mechanism:

Deficiency anemias: These are by far the most common, especially in vulnerable populations such as children, pregnant women and older adults. Treatment is based on replacement of the deficient nutrient, iron, vitamin B12 or folate, through individualized therapy that takes into account clinical urgency, route of administration, oral or parenteral, duration and tolerance. An in-depth discussion of the different strategies, indications and monitoring methods is available on the page dedicated to iron, vitamins and supplements.

Anemias due to erythropoietin deficiency: These are typical mainly of chronic kidney disease; in other conditions, erythropoietic hyporesponsiveness may depend on inflammation, iron restriction or bone marrow disease. ESAs are used only for defined indications and require assessment of thrombotic risk and hypertension; in specific oncologic settings they may reduce survival or promote tumor progression.

Acute blood loss anemias: Massive blood loss requires immediate control of hemorrhage and balanced hemostatic resuscitation; packed red blood cells correct the loss of red cell mass, while circulating volume and perfusion require comprehensive management of fluids and blood components.

Hereditary and rare anemias: Anemias caused by genetic defects, including thalassemias, sickle cell disease, enzyme deficiencies, congenital bone marrow failure syndromes and complex hemoglobinopathies, require an integrated and individualized approach that includes scheduled transfusions, chelation therapy, nutritional support, innovative drugs and, in selected cases, stem cell transplantation. The detailed approach is discussed in the section on the therapeutic approach to rare and genetic anemias.

In every setting, personalization of therapy is essential, especially in older adults, patients with multiple diseases and cases of refractory anemia.

Comprehensive clinical management and integrated strategies

Beyond hematologic correction, management of a patient with anemia requires continuous surveillance and the ability to anticipate, recognize and treat possible complications. Regular monitoring of hematologic and clinical parameters, assessment of treatment tolerance and adaptation of the therapeutic regimen according to response are key elements for preventing clinical deterioration and ensuring patient safety.

When causal therapy is insufficient or the response is suboptimal, supportive strategies become essential:

• Management of transfusion complications, including immune hemolytic reactions, iron overload and infections transmitted by blood components;
• Prevention of organ failure in severe chronic anemias;
• Nutritional support, correction of secondary deficiencies and psychological support, particularly in chronic anemias.

These topics are discussed in greater detail on the page about supportive care and management of complications.

At the same time, continuing advances in clinical research are leading to the introduction of new and emerging therapies, including erythroid maturation agents, innovative treatments for refractory anemias, gene therapy and immunomodulation. For the most recent perspectives, see the section on new therapies.

Conclusions

Anemia treatment is a complex pathway that begins with rigorous etiologic diagnosis, proceeds through selection and adjustment of different therapeutic strategies, and is completed by careful management of complications and follow-up. The ultimate goal is recovery of hematologic function and patient quality of life through timely, individualized intervention based on the best available evidence. For more information on each aspect of treatment, dedicated sections are available on erythropoietin and its analogs, iron, vitamins and supplements, blood transfusions, rare and genetic anemias, management of complications and new therapies.

Bibliography
1. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. Geneva: WHO. 2024.
2. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease. Kidney Int. 2026;109(1S):S1–S99.
3. Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892–1902.
4. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol. 2024;204(3):784–804.
5. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219–1231.
6. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843.
7. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50.
8. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–160.
9. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110.
10. Bain BJ, Daniel Y, Henthorn J, de la Salle B, Hogan A, Roy NBA, et al.; British Society for Haematology. Significant haemoglobinopathies: A guideline for screening and diagnosis. Br J Haematol. 2023;201(6):1047-1065.